A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase 1: Determination of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) first without and then with administration of prophylactic G-CSF.
Owen O'Connor, M.D./Ph.D.
United States: Food and Drug Administration
|Herbert Irving Comprehensive Cancer Center||New York, New York 10032|
|Hackensack University Medical Center||Hackensack, New Jersey 07601|
|University of North Carolina||Chapel Hill, North Carolina 27599|
|Cornell University Medical Center||New York, New York 10021|
|Memorial Sloan-Kettering Caner Center||New York, New York 10021|
|Sarah Cannon Cancer Research Institute||Nashville, Tennessee 37203|